APA (7th ed.) Citation

Nauman, M., Vanni, D., Arellano, N., Nguyen, T. T., LaBelle, J., Saygin, C., . . . Elf, S. (2023). BCL-Xl Represents a Novel Therapeutic Target in Type 2 Mutant Calr-Driven Myeloproliferative Neoplasms. Blood, 142(Supplement 1), 3148. https://doi.org/10.1182/blood-2023-190295

Chicago Style (17th ed.) Citation

Nauman, Mirielle, et al. "BCL-Xl Represents a Novel Therapeutic Target in Type 2 Mutant Calr-Driven Myeloproliferative Neoplasms." Blood 142, no. Supplement 1 (2023): 3148. https://doi.org/10.1182/blood-2023-190295.

MLA (9th ed.) Citation

Nauman, Mirielle, et al. "BCL-Xl Represents a Novel Therapeutic Target in Type 2 Mutant Calr-Driven Myeloproliferative Neoplasms." Blood, vol. 142, no. Supplement 1, 2023, p. 3148, https://doi.org/10.1182/blood-2023-190295.